智通财经APP讯，东阳光长江药业(01558)发布公告，公司自主研究及开发的产品艾考磷布韦片(0.3g)(前称为英强布韦片(0.3g))已获中国国家药品监督管理局审批完毕并获准上市。
该产品是中国1类创新药，该药适用于与磷酸萘坦司韦胶囊联用，治疗初治或干扰素经治的基因1、2、3、6型成人慢性丙型肝炎病毒(HCV)感染，可合并或不合并代偿性肝硬化。
集团不仅拥有完整的药物产品组合，还在基层治疗市场展现出更强的竞争优势，有望成为国内丙肝药物市场的领军企业。此前，集团的一类创新药物磷酸依米他韦胶囊已于2020年正式获批准上市，并成功进入国家医保目录。随着艾考磷布韦片的获批上市，不仅标志着集团在新药研发领域的重大突破，进一步完善集团在国内丙肝药物市场的产品布局，为广大患者提供质价双优的用药选择以外，亦将进一步巩固集团在丙肝治疗领域的竞争优势，显著提升集团在国内创新药企中的领先地位。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.